Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis
Background - Liver metastasis of cutaneous melanoma (CM) correlates with a decreased response to immune checkpoint inhibition (ICI). Here, we investigated whether neoadjuvant ICI protects against liver metastasis to prevent the development of therapy resistances. - Methods - A stage II CM was modele...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 November 2025
|
| In: |
Cancer letters
Year: 2025, Jahrgang: 632, Pages: 1-12 |
| ISSN: | 1872-7980 |
| DOI: | 10.1016/j.canlet.2025.217950 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.canlet.2025.217950 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0304383525005191 
|
| Verfasserangaben: | Sebastian A. Wohlfeil, Céline Weller, Bianca Dietsch, Dennis Alexander Agardy, Tamara Boschert, Sheila A. Vormehr, Christof Dormann, Niklas Straub, Verena Häfele, Michael Platten, Sergij Goerdt, Cyrill Géraud |
| Zusammenfassung: | Background - Liver metastasis of cutaneous melanoma (CM) correlates with a decreased response to immune checkpoint inhibition (ICI). Here, we investigated whether neoadjuvant ICI protects against liver metastasis to prevent the development of therapy resistances. - Methods - A stage II CM was modeled by intracutaneous injections of WT31 or B16F10 luc2 melanoma cells. Combined ICI (anti-PD-1/anti-CTLA-4) was applied in murine models of hepatic melanoma metastasis comparing neoadjuvant or adjuvant regimens. Immune cell composition and responses in the liver and CMs were comparatively analyzed by scRNA-Seq, flow cytometry, immunofluorescence, in situ hybridization and multiplex cytokine assays. - Results - Neoadjuvant ICI resulted in improved protection against liver metastasis in comparison to adjuvant therapy. This superior response was associated with an expansion of T cells in CMs, the peripheral blood and the liver. An increased expression of TH1-associated markers and a downregulation of TH2-associated markers were detected in T cells from CMs and livers of mice by scRNA-Seq and immunofluorescence after neoadjuvant ICI. Analysis of hepatic cytokines also revealed lower levels of TH2-associated IL-4 and of IL-15. - Conclusion - Our data demonstrate that neoadjuvant ICI provides superior protection against hepatic melanoma metastasis with a shift towards an anti-tumor TH1 immune response. Therefore, neoadjuvant ICI is a promising therapeutic option for CM to prevent the development of organ-specific therapy resistance mechanisms. |
|---|---|
| Beschreibung: | Online verfügbar: 24 Juli 2025, Artikelversion: 15. August 2025 Gesehen am 17.11.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1872-7980 |
| DOI: | 10.1016/j.canlet.2025.217950 |